Table II.

Effect of yeast and/or paclitaxel treatment on T-helper lymphocytes (CD4⁺) infiltrated and cytotoxic lymphocytes (CD8⁺) infiltrated in tumor tissue.

	Parameters
Groups	% CD4+ T cells	% change from EAC group	% CD8+ T cells	% change from EAC group
EAC	28.11±0.27		11.48±0.45
Yeast	44.10±1.4C	56.9	20.05±0.29C	74.6
Paclitaxel-H	41.76±0.45C	48.6	16.17±0.66C,D	40.8
Paclitaxel-L	38.76±1.1C,D,e	37.9	13.18±0.39D,E	14.8
Yeast + Paclitaxel-H	48.35±0.76C,E,F	72.0	22.20±0.36C,d,E,F	93.3
Yeast + Paclitaxel-L	43.16±0.97C,F,G	53.6	18.55±0.92C,D,e,F,G	61.5

Data are expressed as mean ± SE of 5 mice/group.

^CP<0.01, significantly different from the EAC group.

^dP<0.05

^DP<0.01, significantly different from the yeast-treated EAC group.

^eP<0.05

^EP<0.01, significantly different from the paclitaxel-H-treated EAC group.

^FP<0.01, significantly different from the paclitaxel-L-treated EAC group.

^GP<0.01, significantly different from the yeast + paclitaxel-H-treated EAC group. EAC, Ehrlich ascites carcinoma. Groups: EAC, mice bearing tumors receiving intratumoral (i.t.) injections of PBS; Yeast, mice bearing tumors receiving intratumoral (i.t.) injections of yeast (1×10⁷ cells/ml); paclitaxel-H, mice bearing tumors receiving paclitaxel at a high dose (10 mg/kg); paclitaxel-L, mice bearing tumors receiving paclitaxel at a low dose (2 mg/kg); Yeast + Paclitaxel-H, mice bearing tumors receiving yeast plus paclitaxel-H; Yeast + Paclitaxel-L, mice bearing tumors receiving yeast plus paclitaxel-L.